MedPath

国药集团威奇达药业有限公司

Ownership
-
Established
2002-09-30
Employees
-
Market Cap
-
Website
www.weiqida.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

116

NMPA:116

Drug Approvals

Amoxicillin and Clavulanate Potassium for Suspension

Product Name
阿莫西林克拉维酸钾(4:1)干混悬剂
Approval Number
国药准字H10970407
Approval Date
Nov 7, 2023
NMPA

Amoxicillin and Clavulanate Potassium for Suspension

Product Name
阿莫西林克拉维酸钾(4:1)干混悬剂
Approval Number
国药准字H10970406
Approval Date
Nov 7, 2023
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20064875
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium

Product Name
头孢呋辛钠
Approval Number
国药准字H20064874
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20066954
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20066950
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20064877
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20064878
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20066953
Approval Date
Dec 28, 2020
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20064876
Approval Date
Dec 28, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.